Acuitas Therapeutics

What Acuitas Therapeutics does

Acuitas Therapeutics is a Vancouver-based, privately held biotechnology company founded in 2009 that develops and licenses lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics. Operating on a pure partnership model, the company does not develop its own drugs; instead it licenses its proprietary LNP platform to pharmaceutical and biotechnology partners across preclinical optimization, clinical development, regulatory approval, and commercialization. Revenue is generated through licensing, royalty, and collaboration agreements rather than direct product sales.

The company's core technology is a clinically validated LNP delivery platform underpinned by proprietary ionizable lipid formulations, including the trademarked ALC-315™ lipid, designed to enable intracellular delivery of mRNA, siRNA, gene therapy payloads, CRISPR-based constructs, and other nucleic acid modalities. The platform has been validated through two FDA-approved products: ONPATTRO® (Alnylam's siRNA therapeutic for hereditary transthyretin-mediated amyloidosis) and COMIRNATY® (Pfizer-BioNTech's mRNA COVID-19 vaccine). Thirty-three partnered clinical trials have been initiated in the last three years, and Acuitas scientists have contributed over 40 peer-reviewed publications in Science, Nature, and Cell in the past two years.

In January 2026, Acuitas acquired a majority stake in Montreal-based RNA Technologies & Therapeutics, adding RNA construct design IP and small-batch GMP-grade manufacturing capacity. Subsequent 2026 partnerships with Sanofi, Eli Lilly, Circio, and Genflow Biosciences extend the platform into CRISPR epigenetic silencing, in vivo CAR-T, and SIRT6 gene therapy, respectively. The company maintains a lean headcount of 11-50 employees and reaches a global customer base exclusively through direct strategic partnerships rather than traditional sales or distribution channels.

Name

Acuitas Therapeutics

Legal name

Acuitas Therapeutics

Website

https://acuitastx.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Acuitas Therapeutics is a Vancouver-based privately held biotech that develops proprietary lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, licensing it exclusively to pharma and biotech partners without developing its own drugs. The platform is clinically validated through two FDA-approved products, ONPATTRO and COMIRNATY.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology / Nucleic Acid Therapeutics Enablement

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

Keywords

• Lipid nanoparticle delivery
• Nucleic acid therapeutics
• MRNA vaccine delivery
• LNP technology licensing
• Gene therapy delivery

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. LNP Technology Licensing and Partnership: Acuitas generates revenue through strategic partnerships with pharmaceutical and biotech companies, licensing their LNP delivery technology to enable the development of nucleic acid therapeutics, gene therapies, and vaccines. The company works with partners from preclinical optimization through clinical trials, regulatory approval, and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Acuitas Therapeutics provides proprietary lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, enabling pharmaceutical and biotechnology partners to develop mRNA vaccines, gene therapies, CRISPR-based therapies, and RNAi drugs. The company does not develop its own drugs; instead it licenses its clinically validated LNP delivery platform and provides formulation, optimization, and development support to partners from preclinical optimization through clinical trials, regulatory approval, and commercialization.

Product overview

Acuitas Therapeutics offers a unified LNP delivery technology platform for nucleic acid therapeutics. The company does not develop its own drugs but provides its globally validated, best-in-class lipid nanoparticle delivery systems exclusively to pharmaceutical and biotechnology partners. The core platform includes proprietary lipid formulations such as ALC-315™ lipid, which is applied in cancer vaccines and prophylactic vaccines. Their technology has been used in two approved commercial products (ONPATTRO® and COMIRNATY®) and enabled over 33 clinical trials for partnered programs.

Differentiator

Problem solved

Functional benefit

Products and services

• LNP Delivery Technology Platform Core proprietary lipid nanoparticle (LNP) delivery technology platform enabling the intracellular delivery of nucleic acid payloads for pharmaceutical and biotechnology partners developing mRNA vaccines, gene therapies, CRISPR-based therapies, and RNAi drugs. The platform is clinically validated through two approved products and is licensed/exclusively used by partners from preclinical optimization through clinical trials, regulatory approval, and commercialization.
• ALC-315™ Lipid A novel proprietary ionizable lipid component used in LNP formulations designed to improve the potency and safety of mRNA therapies, with application in cancer vaccines and prophylactic vaccines.

Quantifiable outcome

• Two approved products on the market using Acuitas' LNP technology
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• SanoficoreStrategic or Co-development Partner · 28 May 2026Strategic collaboration for CRISPR-based epigenetic silencing therapy development using LNP delivery technology for STX-1150 targeting PCSK9 to lower LDL-C.
• Eli LillycoreStrategic or Co-development Partner · 28 May 2026Strategic collaboration for CRISPR-based epigenetic silencing therapy development using LNP delivery technology.
• Genflow BiosciencescoreTechnology or Integration · 20 April 2026Genflow Biosciences partnered with Acuitas Therapeutics to evaluate lipid nanoparticle delivery systems for its SIRT6 gene therapy platform. Under the agreement, Acuitas formulates Genflow's mRNA payload using its LNP platform for preclinical evaluation studies. The collaboration is fully funded by Acuitas with no cash consideration or dilution to Genflow shareholders, providing access to clinically proven delivery technology at no cost. Data generated from preclinical studies will inform future development decisions including delivery optimization and potential partnering arrangements for Genflow's SIRT6 platform targeting age-related diseases.
• CirciocoreTechnology or Integration · 16 April 2026Acuitas Therapeutics and Circio entered a technology evaluation agreement to assess whether Acuitas' lipid nanoparticle (LNP) technology can be combined with Circio's circular RNA expression platform (circVec) for novel in vivo CAR-T therapy targeting cancer and autoimmune diseases.
• RNA Technologies & TherapeuticscoreStrategic or Co-development Partner · 8 January 2026Acuitas acquired a majority stake in Montreal-based RNA Technologies & Therapeutics (RNA T&T), a company specializing in RNA construct design and manufacturing. The two Canadian biotech firms continue operating independently while gaining streamlined access to complementary optimization and manufacturing expertise for RNA-LNP therapeutics development. RNA T&T was co-founded by Nobel laureate Dr. Drew Weissman and scientist Dr. Mohamad-Gabriel Alameh, who notably contributed the RNA design for the first personalized CRISPR therapy administered to a patient. The investment enables RNA T&T to expand its operational footprint, further develop its proprietary algorithmic platform for RNA sequence optimization, and grow capabilities in small-batch GMP-grade production of personalized therapies.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Genevant Sciences: Genevant Sciences is a lipid nanoparticle delivery technology company that licenses its LNP platform to nucleic acid therapeutics developers. It is the most direct competitor to Acuitas in the LNP licensing business model, serving the same pharma/biotech partner base with overlapping ionizable-lipid chemistries.
• Arcturus Therapeutics: Arcturus develops its own LNP-enabled mRNA therapeutic candidates and also engages in LNP technology collaborations. It is a direct peer in that it both develops and out-licenses lipid nanoparticle delivery technology for nucleic acid payloads, competing for partner programs with Acuitas.
• Precision NanoSystems (a Danaher / Cytiva company): Precision NanoSystems develops LNP formulation technologies and instrumentation for nucleic acid delivery, serving pharma and biotech partners with both technology licensing and manufacturing scale-up services. Comparable to Acuitas as an LNP-focused platform provider with development and CDMO-adjacent capabilities.

Emerging players

• Sirnaomics: Sirnaomics develops RNAi therapeutics with proprietary polypeptide-based and nanoparticle delivery systems, including LNP-formulated candidates. Comparable as an emerging nucleic-acid-delivery player with overlapping target indications (oncology, fibrosis) and partner profile to Acuitas' licensees.
• eTheRNA immunotherapies: eTheRNA develops mRNA-based immunotherapies and is building internal lipid-based delivery capabilities for cancer and infectious-disease applications. Comparable to Acuitas as an emerging player in the RNA/LNP delivery space with a more therapeutics-oriented focus.
• Codiak BioSciences: Codiak developed exosome-based delivery platforms (engEx) for nucleic acid and protein payloads as an alternative to LNP. Comparable as a delivery-platform peer addressing the same therapeutic developers with a non-LNP alternative, providing competitive context on next-generation delivery modalities.

Broad incumbents

• Moderna: Moderna is a leading mRNA therapeutics company with an internal proprietary LNP platform used across its vaccine and therapeutic pipeline. It is a broad incumbent because, while it does not license LNP externally, its scale and in-house delivery R&D set the competitive benchmark for LNP performance.
• BioNTech: BioNTech co-developed COMIRNATY (one of the two FDA-approved products using Acuitas' LNP) and operates substantial internal LNP R&D. As a large oncology and infectious-disease mRNA company, BioNTech is comparable both as a partner/customer of Acuitas and as a competitor developing proprietary LNP alternatives.
• CureVac: CureVac is an mRNA therapeutics company with proprietary lipid nanoparticle and other delivery formulations used across its vaccine and oncology pipeline. Comparable as a peer that both develops its own LNP chemistry and competes for nucleic acid therapeutic partnerships.
• Alnylam Pharmaceuticals: Alnylam developed ONPATTRO using Acuitas' LNP and is the leading RNAi therapeutics company. It is comparable as Acuitas' first commercial LNP licensee and as a company actively pursuing alternative siRNA delivery chemistries (GalNAc conjugates) that could reduce reliance on LNP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/acuitastx
• LinkedInlinkedin.com/company/acuitastx

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acuitas Therapeutics